Hemispherian, an Oslo, Norway-based preclinical pharmaceutical firm, raised $2.9M in the primary tranche of a Series A funding.
The spherical was led by Meneldor, with participation from Kistefos AS, Kvantia AS, and Steven Powell.
The firm intends to make use of the funds to help its drug improvement actions, develop its preclinical pipeline and advance its lead therapeutic compounds in the direction of medical improvement.
Led by CEO Zeno Albisser, Hemispherian is a pharmaceutical firm targeted on growing a novel class of small molecule medicine referred to as GLIX. GLIX compounds goal the TET2 enzyme and activate the DNA harm response ensuing in most cancers cell loss of life. The firm’s lead compound, GLIX1, is in late-stage preclinical improvement for the remedy of glioblastoma multiforme, a lethal most cancers of the central nervous system and the main trigger of loss of life by illness in kids. Hemispherian is additional targeted on growing a companion diagnostic device to help affected person choice for optimum therapeutic response to GLIX1.